Takeda Pharmaceutical Company Limited (NYSE:TAK) Stock Holdings Lifted by Versant Capital Management Inc

Versant Capital Management Inc increased its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 1,179.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,130 shares of the company's stock after acquiring an additional 23,166 shares during the quarter. Versant Capital Management Inc's holdings in Takeda Pharmaceutical were worth $374,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of TAK. Farther Finance Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at $52,000. Cromwell Holdings LLC purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at $61,000. Venturi Wealth Management LLC grew its holdings in shares of Takeda Pharmaceutical by 554.7% during the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after buying an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC grew its holdings in shares of Takeda Pharmaceutical by 65.0% during the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after buying an additional 2,029 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 1.4%

Shares of TAK stock traded up $0.21 on Friday, reaching $15.01. 1,725,292 shares of the company's stock traded hands, compared to its average volume of 1,938,305. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The company has a market capitalization of $47.76 billion, a P/E ratio of 37.53, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The business's 50 day moving average price is $14.66 and its two-hundred day moving average price is $14.05.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The firm had revenue of $7.34 billion during the quarter, compared to analysts' expectations of $8.02 billion. On average, equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.